

**MATERIAL CHANGE REPORT**

**Item 1: Name and Address of Reporting Issuer**

Kidani Capital Partners Inc. (“**Kidani**”)  
804-750 West Pender Street  
Vancouver, BC V6C 2T7

1040426 B.C. Ltd. (“**1040426**”)  
804-750 West Pender Street  
Vancouver, BC V6C 2T7

1040428 B.C. Ltd. (“**1040428**”)  
804-750 West Pender Street  
Vancouver, BC V6C 2T7

1040433 B.C. Ltd. (“**1040433**”)  
804-750 West Pender Street  
Vancouver, BC V6C 2T7

1040436 B.C. Ltd. (“**1040436**”)  
804-750 West Pender Street  
Vancouver, BC V6C 2T7

1040440 B.C. Ltd. (“**1040440**”)  
804-750 West Pender Street  
Vancouver, BC V6C 2T7

Genix Pharmaceuticals Corp. (formerly 1040442 B.C. Ltd.) (“**Genix**”)  
804-750 West Pender Street  
Vancouver, BC V6C 2T7

**Item 2: Date of Material Change**

October 29, 2015.

**Item 3: News Release**

A news release was filed on SEDAR at [www.sedar.com](http://www.sedar.com) on October 29, 2015.

**Item 4: Summary of Material Changes**

Kidani, 1040426, 1040428, 1040433, 1040436, 1040440 and Genix are pleased to announce that on October 29, 2015 (the “**Effective Date**”), they completed a statutory arrangement under a plan of arrangement (the “**Arrangement**”).

**Item 5: Full Description of Material Change**

Kidani, 1040426, 1040428, 1040433, 1040436, 1040440 and Genix are pleased to announce that on the Effective Date, they completed the Arrangement. As a result of completing the Arrangement, 1040426, 1040428, 1040433, 1040436, 1040440 and Genix became reporting issuers in the provinces of British Columbia and Alberta.

Completion of the Arrangement as set forth in the arrangement agreement and plan of arrangement dated July 20, 2015 (the “**Arrangement Agreement**”) among Kidani, 1040426, 1040428, 1040433, 1040436, 1040440 and 1040442 B.C. Ltd. was approved by the shareholders of Kidani on August 14, 2015 and by a Final Order granted by the Supreme Court of British Columbia on August 19, 2015 in accordance with Part 9 of the Business Corporations Act (British Columbia).

**1040426 B.C. Ltd.:**

Under the terms of the Arrangement Agreement and on the Effective Date, 1040426 issued a total of 396,600 common shares to the shareholders of Kidani at a deemed price of \$0.01 per common share.

The CUSIP number for the common shares of 1040426 is 68247A107.

As of the Effective Date, the board of directors of 1040426 are Christopher P. Cherry, Robert M. Dzisiak and Stephen Brohman and the sole officer is Christopher P. Cherry as President, CEO and CFO.

**1040428 B.C. Ltd.:**

Under the terms of the Arrangement Agreement and on the Effective Date, 1040428 issued a total of 396,600 common shares to the shareholders of Kidani at a deemed price of \$0.01 per common share.

The CUSIP number for the common shares of 1040428 is 68247B105.

As of the Effective Date, the board of directors of 1040428 are Christopher P. Cherry, Robert M. Dzisiak and Stephen Brohman and the sole officer is Christopher P. Cherry as President, CEO and CFO.

**1040433 B.C. Ltd.:**

Under the terms of the Arrangement Agreement and on the Effective Date, 1040433 issued a total of 396,600 common shares to the shareholders of Kidani at a deemed price of \$0.01 per common share.

The CUSIP number for the common shares of 1040433 is 68247C103.

As of the Effective Date, the board of directors of 1040433 are Christopher P. Cherry, Robert M. Dzisiak and Stephen Brohman and the sole officer is Christopher P. Cherry as President, CEO and CFO.

**1040436 B.C. Ltd.:**

Under the terms of the Arrangement Agreement and on the Effective Date, 1040436 issued a total of 396,600 common shares to the shareholders of Kidani at a deemed price of \$0.01 per common share.

The CUSIP number for the common shares of 1040433 is 68247D101.

As of the Effective Date, the board of directors of 1040436 are Robert M. Riley, Jonathan Samuda and Andrew Mugridge and the sole officer is Robert M. Riley as CEO and CFO.

**1040440 B.C. Ltd.:**

Under the terms of the Arrangement Agreement and on the Effective Date, 1040440 issued a total of 396,600 common shares to the shareholders of Kidani at a deemed price of \$0.01 per common share.

The CUSIP number for the common shares of 1040440 is 6824E109.

As of the Effective Date, the board of directors of 1040440 are Christopher P. Cherry, Robert M. Dzisiak and Stephen Brohman and the sole officer is Christopher P. Cherry as President, CEO and CFO.

**Genix Pharmaceuticals Corp.:**

Under the terms of the Arrangement Agreement and on the Effective Date, Genix issued a total of 396,600 common shares to the shareholders of Kidani at a deemed price of \$0.01 per common share.

The CUSIP number for the common shares of Genix is 37231L106.

As of the Effective Date, the board of directors of Genix are Christopher P. Cherry, Robert M. Dzisiak and Stephen Brohman and the sole officer is Christopher P. Cherry as President, CEO and CFO.

**Item 6: Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable.

**Item 7: Omitted Information**

None.

**Item 8: Executive Officer**

**For further information regarding each of Kidani, 1040426, 1040428, 1040433, 1040440 and Genix please contact:**

Christopher P. Cherry  
President, CEO & CFO  
T: 604.908.3095  
E: [chris@cherryconsulting.ca](mailto:chris@cherryconsulting.ca)

**For further information regarding 1040436 BC Ltd. please contact:**

Robert M. Riley  
CEO & CFO  
T: 604.889.4302  
E: [robriley@telus.net](mailto:robriley@telus.net)

**Item 9: Date of Report**

October 29, 2015.